LG Life Sciences India Pvt. Ltd is to market in India Venofer, the intravenous (IV) iron manufactured by Vifor (International) Inc., and a Swiss healthcare company. LG Life Sciences has exclusive marketing rights for the product in the Indian market.
The IV iron injection will be launched via scientific meets in Delhi, Mumbai and Chennai. These meetings will be addressed by Roland M. Schaefer, Professor University of Muenster, Germany, and will be attended by leading nephrologists in the respective cities, stated a press release.
Venofer (Iron sucrose injection) is a first-line IV iron choice for the treatment of iron deficiency anaemia in chronic kidney disease patients. Venofer is a US FDA approved product and has a worldwide clinical experience with over 4.6 million patients in more than 80 countries.
The World Health Organisation (WHO) identifies iron deficiency as one of the most prevalent nutrient deficiencies in the world affecting an estimated 2 billion people and causing almost a million deaths each year, the release said.
Vifor (International) Inc. is a Swiss company and part the diversified Galenica Group that is active at all levels of the healthcare market, including research and development, manufacturing, marketing, pre-wholesaling, distribution and retailing of pharmaceuticals.
LG Life Sciences, Ltd. started its activity as a 100 per cent subsidiary in India by the name of LG Life Sciences India Pvt. Ltd. (LGLSI) in 2002 and has been able to establish its significant presence in erythropoietin market with its recombinant Espogen because of world-class quality. LGLSI plans in future to set up its own production and R&D units dedicated to lifesaving and biotechnology products in India so as not only to innovate, manufacture and sell in India but also to build export business to other SAARC, Middle East and African countries.